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“In an age when man has been able to measure most things from an atom to a galaxy, it is 
thus paradoxical that to measure his own size during the most critical and precarious period 
of his life, he still has to depend upon the extreme fallibility of the palpating hand.” 
 
Dobbs and Gairdner 1966   
  
 
 
 
 
 
 
 
 
 
                                           “All of these lines across my face 
    Tell you the story of who I am 
    So many stories of where I've been 
    And how I got to where I am 
    But these stories don't mean anything 
    When you've got no one to tell them to 
    It's true I was made for you” 
 
              “The story” by Phil Hanseroth  
Performed by Brandi Carlile  
 
 
 
 
 
 
 
 
 
 
 
To my FAMILY just as it is 
  
 
  
ABSTRACT 
 
Background: Intrapartum fetal monitoring aims to prevent adverse outcomes due to 
intrapartum asphyxia. Cardiotocography (CTG) is an established method for intrapartum 
monitoring. The method has high sensitivity, but low specificity and is also user-dependent 
and linked to both inter- and intraobserver variability. CTG might increase the risk for 
unnecessary interventions. One suggested method to improve CTG interpretation is 
computerized monitoring. Other possible ways are improved knowledge about risk factors 
and proper use of adjunctive technologies. One common adjunctive technology is fetal scalp 
blood sampling (FBS). Fetal distress is one reason for intrapartum caesarean section, but the 
main reason is dystocia. Today there is no way to predict dystocia. Studies have suggested 
that increased levels of lactate in the uterus correlates with dystocia.     
Materials and Methods: Study 1 is a prospective observational study of 120 women, 
investigating methodological aspects of short-term-variation (STV) as a part of computerized 
fetal monitoring. Paper 2 and 3 study 1070 term pregnancies that underwent FBS. Study 2 is 
an analysis of lactacidemia in FBS compared to different CTG patterns. Study 3 is an analysis 
of risk factors for lactacidemia in FBS. Study 4 is a clinical observational study, of 77 women 
in labor, evaluating if lactate concentration in cervical fluid could be a predictor for dystocia. 
Results: STV values differ between internal and external derived values. The two 
commercial available CTG machines for antenatal STV monitoring perform equal. Late or 
severe variable decelerations in combination with tachycardia are the CTG patterns with 
highest frequency of lactacidemia. Isolated reduced variability in an otherwise normal CTG 
trace is not linked to lactacidemia. Risk factors correlated to lactacidemia are minor language 
barriers and active bearing down. Increased concentration of lactate in cervical fluid seems to 
predict operative delivery.  
Conclusions: These results suggest several implications on intrapartum monitoring. 
Intrapartum STV values should preferably be derived from internal monitoring. The same 
cut-off values could be used for the two commercial available machines for STV monitoring. 
Late and severe variable decelerations correlate to lactacidemia to the same extent. Isolated 
reduced variability is not a sign of hypoxia. Use of interpreters can be a possible way to avoid 
adverse neonatal outcome. Cervical lactate might be a possible tool in predicting dystocia.       
 
Key words: Cardiotocography (CTG), Caesarean section, Computerized cardiotocography, 
Dystocia, Fetal blood sampling, Fetal distress, Fetal heart rate, Fetal monitoring, Lactate, 
Language barriers, Metabolic acidosis, Risk factors, Short term variation 
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1 BACKGROUND 
Introduction 
Introduction 
Obstetric care is unique because we usually treat and care for two healthy individuals. 
Pregnancy and to give birth is something healthy. Some pregnant women can suffer from a 
disease and develop complications during pregnancy and delivery. This could be a slow 
process, but also an abrupt unexpected life-threatening event for both mother and fetus. 
To give birth is for most women a life event with great expectations. The role of the obstetric 
care is to make this life event as safe and as natural as possible. The goal is a healthy mother 
and healthy new born child. Being a health care professional in this situation is a balance 
between avoiding unnecessary medical surveillance/intervention and to maintain a safe 
delivery process. We do not want to take unnecessary risks but we want to intervene as little 
as possible. 
To maintain this sophisticated balance intrapartum monitoring is essential. The aim with 
intrapartum monitoring is to deliver healthy fetuses, with minimal risks and complications for 
the woman in labor, our surveillance should help us to prevent and not to predict.       
 
Fetal outcomes to avoid  
For a fetus the delivery is a challenge, after nine months in the warm, well-nourished 
environment in the uterus the fetus becomes exposed to contractions. All oxygen and energy 
reaches the fetus through the placenta and the umbilical cord. During the delivery process this 
circulation is affected by the contractions and from time-to-time decreased circulation could 
be a too big challenge for the vulnerable fetus.1 A healthy fetus has the capacity to tolerate the 
stress of being born. The fetus uses defence mechanisms regulated by the autonomic nervous 
system, one is the ability to redistribute blood to central organs (heart, brain and adrenals).2  
A low pH in fetal blood has two main reasons. The first is accumulation of carbon dioxide 
(CO2) due to reduced elimination of CO2 via the umbilical cord. This is called respiratory 
acidosis. This is seldom a problem, since the fetus has the capacity to get rid of the CO2 
immediately after delivery.2 The other reason for pH to decrease is elevated levels of acids, 
mainly lactate produced due to anaerobic metabolism. Anaerobic metabolism occurs due to 
lack of oxygen, the process generates a little bit more than 5% of the energy that had been 
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produced if oxygen had been present. In an anaerobic metabolism the cell uses glucose to 
produce pyruvate (glycolysis). Pyruvate will be converted to lactate with hydrogen ions as a 
consequence. This is called metabolic acidosis. This will increase the lactate levels in the 
tissue, but also decrease the pH value.3   
If the process of hypoxia continues, chemoreceptors can be affected and thereby the fetal 
heart rate. The elevated concentrations of stress hormones cause a vasoconstriction and an 
elevated blood pressure. In elongation both hypoxia and ischemia occur in the tissues. Brain 
damage is a very late stage in this process and the brain damage is not a primary injury but a 
consequence of a process initiated by the acidosis. This process and the condition with low 
blood flow and oxygenation is called asphyxia.1, 2  
 
Figure 1. A needle for every child born at Karolinska University hospital in Solna 2011. Photo by Stina Wretler, 
New year’s eve 2011 
 
 
Asphyxia can occur during pregnancy, intrapartum or during the first hours of life. Asphyxia 
which occur post-partum is often caused by fetal diseases. Asphyxia during pregnancy is 
often referred to as chronic hypoxia. It is caused by maternal diseases and conditions as 
preeclampsia, diabetes and immunization. These fetuses could get permanent brain damage 
and the pregnancy could also end with stillbirth.2  
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Intrapartum asphyxia can occur due to an obstetric catastrophe such as rupture of the uterus, 
placenta abruption, umbilical cord prolapse or severe maternal hypotension. Even so the main 
reason for intrapartum asphyxia is the delivery process, with its uterine contractions.2  
Most fetuses suffering from intrapartum asphyxia recover in a few days. Still intrapartum 
asphyxia can cause neonatal encephalopathy (NE).4, 5 Encephalopathy develops during the 
first 24 hours after birth and is not possible to predict. Asphyxia also affects other organs than 
the brain, but these effects are mostly reversible. It is the grade of how affected the brain is, 
which determine the long term prognosis.2 Sarnat and Sarnat defined criteria for NE (table 
1).6 NE is not always associated with asphyxia or intrapartum events. The causes are 
heterogeneous and multifactorial, many pathways start in the antepartum period.4, 5, 7-9 The 
correlation between NE and intrapartum events can partly be explained by the fact that 
fetuses with damages which will lead to NE present their first symptoms during delivery.10  
Many cases of NE are associated with events beyond the control of the clinicians. Suboptimal 
care could be a partial factor in some cases. Many of these cases occur in low risk 
pregnancies why great efforts are needed to prevent them.11  
 
Table 1. Criteria and staging of Neonatal encephalopathy (NE) 
Table 1 - Neonatal encephalopathy
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Stage I Duration <24h, hyperalertness, uninhibited Moro and 
stretch reflexes, sympathetic effects and a normal 
electroencephalogram (EEG). 
Stage II Obtundation, hypotonia, strong distal flexion and 
multifocal seizures. EEG with periodic pattern 
sometimes preceded by continuous delta activity. 
Stage III Stuporous, flaccid and brain stem and autonomic 
functions suppressed. EEG isopotential or with 
infrequent periodic discharges.  
 
When encephalopathy is correlated to an asphyxia it is called hypoxic-ischemic-
encephalopathy (HIE).2 Most infants with HIE stage one becomes healthy. Infants with 
moderate to severe HIE have an increased risk for neurological and cognitive sequelae. 25% 
of infants with moderate HIE develop some kind of neurological sequela. Among infants with 
severe HIE only 50 % will survive the first years of life and among survivors 75-100% has 
 4 
severe neurological sequela. Magnetic resonance imaging (MRI) is a good method to 
evaluate neurological damage after intrapartum asphyxia.2 
In this context the most feared long term complication is cerebral palsy. Cerebral palsy (CP) 
is uncommon with an incidence of approximately 200 children/year in Sweden12 and most 
cases of CP are caused by other reasons than intrapartum complications.8, 13, 14 Intrapartum 
event as cause of asphyxia related to neonatal morbidity and mortality is rare, but it is 
preventable and therefore important to investigate.15 
It is complicated to find a causal relationship between intrapartum events and later diagnosed 
CP, since some fetuses with asphyxia have other causes which could be linked to the CP or 
could have made the fetus more fragile and more likely to become distressed. CP has often a 
multifactorial pathway. The proportion of CP which could be directly associated to 
intrapartum hypoxia is estimated to less than 10 %.8, 13, 14, 16 Since CP is not solely linked to 
asphyxia it could be problematic to use as a measure of perinatal care.  
Umbilical cord artery pH and base deficit (BD) are important diagnostic tools regarding 
intrapartum asphyxia, but the stage of HIE is a better predictor for prognosis.2 An umbilical 
cord artery BD >12 mmol/L or pH <7.00 confirms that a fetus has been exposed to hypoxia.7, 
8, 17, 18 In 1999 the international cerebral palsy task force published an international consensus 
statement about intrapartum events and CP. They had defined special criteria to define an 
acute intrapartum hypoxic event which could support causal relationship to the future 
handicap.8 Umbilical cord pH is used clinically to access information about how the fetus has 
handled the delivery process. Umbilical cord artery pH is widely accepted as a predictive 
neonatal outcome.19 A low Apgar score at 5 minutes is associated to birth asphyxia and an 
increased risk for CP, epilepsy, seizures and mental retardation. 20, 21 
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Criteria for an acute intrapartum hypoxic event  
Essential criteria 
1. Evidence of metabolic acidosis at birth; umbilical arterial cord or very early neonatal blood samples 
(pH<7 and base deficit >12 mmol/L) 
2. Early onset of severe or moderate neonatal encephalopathy in infants of  ≥34 weeks gestation 
3. Cerebral palsy of the spastic quadriplegic or dyskinetic type 
Criteria that together suggest an intrapartum timing but by themselves are non-specific 
4. A sentinel (signal) hypoxic event occurring immediately before or during labor 
5. A sudden, rapid , and sustained deterioration of the fetal heart rate pattern usually after the hypoxic 
sentinel event where the pattern was previously normal 
6. Apgar score of 0-6 for longer than 5 minutes 
7. Early evidence of multisystem involvement 
8. Early imaging evidence of acute cerebral abnormality 
 
In conclusion important outcomes in this area of research are Apgar score, umbilical cord 
blood gas and lactate analyses, NE, HIE and CP. Since seizures are one of the more severe 
symptoms and a well-defined symptom it is often used as a substitute outcome in this area.  
 
Maternal outcomes to avoid 
One concern with intrapartum monitoring is that we want to avoid unnecessary interventions. 
By interventions we usually mean instrumental vaginal deliveries and caesarean sections. In 
developed countries these are generally safe procedures, but they are connected to more risk 
than spontaneous vaginal deliveries in the whole population. Still these interventions are 
necessary procedures for some women and/or fetuses. WHO recommends a caesarean section 
rate between 10 and 15% to maintain the balance with most benefits for women and infants.22 
Worldwide there is a problem with an increasing amount of caesarean sections. 32 % of all 
births in the US were caesarean deliveries 2007.23 The caesarean section rate is also high in 
Asia (27.3%).24 In Sweden we have an increased rate since the 1970ies (5%), but over the last 
years the rate has been relatively stable around 17% (2015).25  
Caesarean sections are linked to several complications for both woman and fetus. For the 
woman caesarean section increases the risk for severe post-partum hemorrhage,26 placenta 
previa and placenta abruption in the following pregnancies,27 unexplained intrapartum 
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stillbirth in future pregnancy28 and uterine rupture in future vaginal deliveries.29 In addition to 
this the woman has the risk for the usual complications to abdominal surgery. There are also 
risks for the fetus one of the most common complications is initial respiratory problems.30 
In the discussion about fetal monitoring the fear is that monitoring might increase 
intervention rate, still the most common reason for intrapartum caesarean section is 
dystocia.31, 32 Aside the increased risk for caesarean section, a long time in labor is also linked 
to a negative experience of childbirth for the woman.33  
     
Risk factors 
When we interpret cardiotocography (CTG) we do not just look at the trace but we also 
assess the woman in labor and evaluate her fetus - a CTG trace should always be 
interpreted in its context.34 In this area we need to find out which risk factors that correlates 
to the different outcomes. The risk factors should be a part in our decision about what the 
fetus can handle. By this follows that the most important risk factors are the ones known 
during pregnancy and labor.  
The thought of dividing pregnancies into high and low risk pregnancies to optimize 
intrapartum care is not new. In the end of the 1960ies a research group tried to identify a risk 
score as help in clinical practice.35 To study risk factors is important because some are 
adjustable and a negative outcome could be prevented. To gain knowledge about risk factors 
scientifically proofed is to make obstetric care less person bound and also a way to optimize 
clinical resources. 
Previous studies have linked different risk factors to different steps in the process of asphyxia 
(table 2).4, 5, 9, 20, 36-41 However, these adverse outcomes are not exclusively caused by birth 
asphyxia, but some are potentially preventable with improved intrapartum management.4, 5, 7, 
8, 11, 14, 15, 37, 42, 43 Most outcomes have multifactorial etiologies.4, 5, 36 Since neither CP nor NE 
are most often not solely caused by asphyxia we cannot take for granted that their risk factors 
are directly associated with asphyxia. Studies have been performed using low Apgar score or 
low pH in umbilical artery as outcome measures for asphyxia.20, 38-41 
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Table 2. Significant risk factors for neonatal outcomes in different studies. 
Title  Country Yeara Study population Outcome Significant risk factors 
Risk Factors for acidemia at 
Birth38  
Sweden 1997 Cohort 23 016; 
249 cases and 249 
controls 
pH in umbilical 
cord artery 
<7.05 
Oxytocin augmentation                     
Meperidine administration                                                        
Breech delivery                                            
Cord entanglement                                                                                 
Male infant gender                                                          
Antepartum risk factors for 
newborn encephalopathy: the 
Western Australian case-
control study5 
Australia 1998 All cases from the 
birth cohort from 
June 1993 to 
September 1995, 
unclear total 
cohort but 164 
cases and 400 
controls.  
 
Moderate or 
severe newborn 
encephalopathy 
Maternal age                                               
Parity                                                      
Maternal employment                                     
No private health insurance                           
Not having drunk alcohol                         
Family history of seizures                
Neurological disease in family                    
Infertility treatment                                                                     
Thyroid disease                                                                                       
Severe pre-eclampsia                                 
Moderate or severe bleeding                 
Clinically diagnosed viral illness                          
Gestational age                                      
Abnormal placenta at delivery                      
Birth weight of the baby       
Intrapartum risk factors for 
newborn encephalopathy: the 
Western Australian case-
control study4  
Australia 1998 All cases from the 
birth cohort from 
June 1993 to 
September 1995, 
unclear total 
cohort but 164 
cases and 400 
controls.  
Moderate or 
severe newborn 
encephalopathy 
Maternal pyrexia                                       
Occipitoposterior position                               
An acute intrapartum event                      
General anaesthesia                               
Operative vaginal delivery                                                    
Intrapartum caesarean section                          
Elective caesarean – protective                                   
Low 5-minute Apgar score: A 
population-based register 
study of 1 Million term 
Births20  
Sweden 2001 Cohort 1 028 705; 
7787 cases 
Apgar score <5 
at 5 min 
Maternal age                                           
Smoking                                                       
Non-Swedish mothers                        
Primiparity                                                  
Gestational age                                       
Epidural analgesia                                                                                                 
Night-time delivery                                                                              
Delivery in August                                                                 
Breeche delivery                                       
Second born twin                                              
Male infant gender                                               
Birth weight  
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Influence of maternal, 
obstetric and fetal risk factors 
on the prevalence of birth 
asphyxia at term in a Swedish 
urban population39  
Sweden 2002 Cohort 42 203 
births; 225 cases 
and 225 controls   
Apgar score <7 
at 5 min 
 
Single civil status                                   
Oxytocin augmentation           
Cardiotocography pattern                       
Intrauterine meconium release                                          
Cord complication                                        
External compression to assist delivery    
Breech delivery                                     
Operative delivery                                   
Neonatal leanness                                         
Birth weight                                     
Perinatal factors associated 
with cerebral palsy in 
children born in Sweden36  
Sweden 2006 2 303 case with CP 
from the Swedish 
Medical Birth 
Registry 1984-
1198 (1.6 million 
infants) 
Cerebral palsy Maternal age                                               
Parity                                                      
Smoking                                                 
Diabetes typ 1                                     
Preeclampsia                                                        
Being a twin                                           
Abruptio placentae                                            
Breech presentation                                                                                   
Vaginal birth                                                                                              
Instrumental delivery                                                                          
Emergency caesarean delivery                        
Preterm delivery                                                                 
Low apgar score                                           
Male infant gender                                       
Birth weight          
Acidemia at birth, related to 
obstetric characteristics and 
to oxytocin use, during the 
last two hours of labor40 
Sweden 2008 Cohort 28 486 
deliveries, 305 
cases and 610 
controls 
pH in umbilical 
cord artery 
<7.05 
Oxytocin augmentation                                    
≥6 contractions per 10 minutes                     
Cord entanglement                                
Risk factors for asphyxia 
associated with substandard 
care during labor37  
Sweden 2010 177 cases, 
1 141 772 controls 
from the Swedish 
Medical Birth 
Register  
Encephalopathy 
caused by 
asphyxia with 
suspected 
substandard care 
during labor 
Maternal age                                                 
Short maternal stature                              
Previous caesarean delivery                          
Diabetes                                                        
Twin                                                       
Gestational age                                               
Induced delivery                                                                                                                                     
Epidural analgesia                                          
Opioid analgesia                                            
Dystocia                                                      
Night-time delivery                                    
Breech                                                          
Male infant gender                                       
Birth weight 
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Antepartum and intrapartum 
risk factors for neonatal 
encephalopathy at term9  
Italy 2010 Cohort 30 580 
infants; 27 cases 
and 100 controls 
Neonatal 
encephalopathy 
Obesity                                                   
Previous caesarean section                                        
Nonreactive FHR before labor               
Abruptio placentae 
Risk factors for severe 
neonatal acidosis41  
France 
and 
Canada 
2011 Cohort of 37 235; 
226 cases and 226 
controls 
pH in umbilical 
cord artery 
<7.00 
Maternal age                                                 
Prior neonatal death                                       
Prior caesarean delivery                      
Abnormal fetal heart rate                                                                           
Thick meconium                                                           
General anesthesia                                    
Uterine rupture                                     
a) Year of publication 
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Fetal monitoring 
Cardiotocography (CTG) 
Cardiotocography (CTG) as a method was suggested and firstly developed by Edward Hon in 
the late 1950ies.44, 45 The method was fast widely accepted even if the knowledge about 
interpreting was deficient. At the same time the method was evaluated in clinical randomized 
studies. In Sweden we started to use CTG in the 1970ies.46  
To proof the value of an already introduced method is a challenge. The challenge becomes 
even greater because of other concurrent advancement.47 Many studies in this area were 
performed in departments were CTG already were in clinical use. One problem to deal with 
was what to compare with; is it relevant to compare with intermittent auscultation with 
Pinard’s stethoscope? Should fetal scalp blood sampling be used in the studies? This makes it 
a complex area for research.  
There have been a lot of studies in this area, many of them with 500 or less included 
women.48, 49 Since the outcomes (NE, CP and perinatal mortality) are rare, the size of these 
studies is a great concern. Presently there are good reviews performed in the area, but some 
studies still need to be mentioned separately, because of their great impact on further studies 
and reviews.  
The largest study is the Dublin randomized controlled trial (RCT) including 12 964 women 
comparing continuous CTG with intermittent auscultation. The study had wide exclusion 
criteria and fetal scalp blood sampling (FBS) was used as adjunctive technology. The study 
found no significant difference in the rate of caesarean delivery (2.4% in the CTG group and 
2.2% in the auscultation group), but a significantly higher amount of forceps deliveries in the 
CTG group (8.2% compared to 6.3%; p<0.0001). The main difference in neonatal outcome 
was that neonatal seizures and persistent abnormal neurological signs followed by survival 
were twice as frequent in the intermittent auscultation group.48  
Another important study is the Athens trial; a RCT comparing continuous intrapartum CTG 
versus intermittent auscultation. This study was performed in a context (Greece) where 
perinatal mortality was more common, than in other comparable study settings. The study 
was performed in non-expert clinics. They did not use adjunctive technologies or switched to 
CTG when they found abnormalities in auscultation. The study was closed prematurely (after 
recruitment of 1428 patients) because an interim analysis showed a higher mortality rate in 
the auscultation group compared to the CTG group. Perinatal death from fetal hypoxia was 
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0% in CTG group and 0.9% in auscultation group (p=0.03). In this study CTG increased the 
rate of surgical intervention for suspected fetal distress (11.2% vs. 4.8% p=0.0001).49    
One of the authors from the Athens trial, is a co-author in a meta-analysis of CTG studies.50 
The meta-analysis includes studies with CTG versus intermittent auscultation. It shows that 
use of CTG leads to decreased perinatal mortality due to fetal distress, but an increased risk 
for caesarean and assisted vaginal delivery. The same analysis is performed excluding the 
Dublin trial and the result is the same. Worth mentioning is the fact that even if this meta-
analysis showed an increased caesarean risk, the caesarean risk in the total electronic fetal 
monitoring group was 5.2%.   
One study performed in California tackles the problem with a rare complication in a different 
and maybe the only correct way.51 This study is a case-control study where they identified all 
children with CP among 155.636 children in four Californian counties and compared with 
randomly selected controls. Retrospectively all information about the CTG patterns during 
delivery was collected. 78 children were included in the study (95 cases with CP but only 78 
underwent CTG monitoring). The study showed an association between CP and late 
decelerations, decreased beat-to-beat variation or both in CTG. They also stress that these 
CTG patterns often are false positive. They calculated that 4 out of 100.000 infants had 
preventable CP, but 2324 unnecessary interventions per infant need to be performed to 
prevent one case of CP.   
Finally we have a Cochrane review from 2017 with purpose to investigate the value of 
continuous CTG monitoring.52  In this review, comparing continuous CTG versus 
intermittent CTG and intermittent auscultation, over 37 000 women were included. The 
review concluded that CTG decreased the risk for neonatal seizures, but could not found any 
decreased risk for other neonatal outcomes. Continuous CTG increased the risk for caesarean 
section and for instrumental delivery. 
The conclusion is that CTG might protect against neurological damage due to asphyxia, but 
that the price is an increased rate of operative deliveries. 
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The usage of CTG  
Despite the doubtful scientific evidence for the use of CTG. CTG is one of the most widely 
used techniques for intrapartum fetal monitoring.52, 53 
In 2015 International Federation of Gynecology and Obstetrics (FIGO) published updated 
consensus guidelines about intrapartum fetal monitoring. These documents are a unique 
overview of intrapartum monitoring, the physiology beyond it and adjunctive technologies.53-
57 FIGO admit that intermittent auscultation is reliable in low-risk pregnancies even if half of 
the panel members considered continuous monitoring optional in second stage of labor.55 
Despite scientific proof most experts believed that continuous CTG should be used in 
monitoring in risk pregnancies/deliveries and as a complement when intermittent auscultation 
detects anomalies. The documents conclude that regular CTG training is necessary and that 
the risk with CTG is unnecessary intervetions.53 FIGO stresses the need for adjunctive 
technologies due to high sensitivity and low specificity in CTG monitoring and that the 
existing data in summary support that FBS reduces interventions. Other suggested adjunctive 
technologies is fetal scalp stimulation, STAN and computer analysis of CTG.54      
In Sweden the use of CTG is “gold standard” in intrapartum fetal surveillance. According to a 
survey from 2010 all Swedish departments use admission test (a first CTG trace when a 
woman arrive to a labor ward). Most departments use either continuous or intermittent CTG 
during first stage of labor.58 The Swedish national board of Health and Welfare (in Swedish 
Socialstyrelsen) recommends admission test and intermittent CTG during first stage of labor 
in low-risk pregnancies, otherwise continuous CTG.59 There is one Swedish prospective 
randomized trial performed, published in 1994, studying intermittent versus continuous CTG 
in low risk labors.60 This study concluded that intermittent CTG is a safe as continuous 
monitoring in low-risk labors.   
2015 Swedish agency for Health Technology Assessment and Assessment of Social Services 
(SBU) published a commentary on previous editions of the two Cochrane reviews about 
admission test and continuous CTG monitoring during labor.46, 52, 61 SBU criticize that the 
included studies are published 20 to 40 years ago and it is doubtful if the results could be used 
in a Swedish context nowadays. This conclusion mirrors the reasons for why CTG is so 
widely used despite the weak scientific proofs. It is totally clear that the fetuses do not get 
harmed by CTG, probably the opposite. Potentially CTG increases the rates of operative 
deliveries. But still the increase is small compared to the overall risk. The caesarean section 
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rate in the whole study population in the Cochrane review was 4.5% compared to 17% in 
Sweden 2011.25   
In 2002 85% of all births in the US were monitored with CTG.62 A population study from the 
US shows decreased perinatal mortality most likely due to CTG.63 The American Congress of 
Obstetrics and Gynecologists (ACOG) accepts intermittent auscultation in low risk 
pregnancies. They recommend continuous CTG monitoring in high risk conditions.34    
 
CTG interpretation 
CTG monitors the fetal heart rate with either a Doppler probe on the mother’s abdomen or 
through a scalp electrode applied to the fetal head. The external device uses the Doppler 
function to detect movements in the fetal heart. The internal device detects the R-wave of 
fetal electrocardiogram (ECG). The contractions are monitored by another probe on the 
mother’s abdomen.53   
How we should interpret CTG is an ongoing debate.64-66 Which parameters to take into 
consideration seem accepted.34, 53, 66-70 A CTG description should include five different 
variables: baseline fetal heart rate, variability, occurrence of accelerations, occurrence of 
decelerations and frequency of contractions. There exist many different guidelines about how 
to interpret CTG.34, 53, 66-70 Most guidelines are consensus documents and define variables 
similarly. The Swedish Society of Obstetrics and Gynecology (SFOG) has published CTG 
guidelines, updated 2016 (figure 2).70  
 
Figure 2. The Swedish CTG interpretation guidelines from SFOG.
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A normal baseline fetal heart rate is defined as a heart rate between 110 and 160 beats per 
minute (bpm). Normal variability is defined as variability between 5 and 25 bpm. 
Acceleration is defined as an increase in fetal heart rate with at least 15 bpm for at least 15 
seconds. Decelerations are defined as a decrease in fetal heart rate and could be described as 
early or late decelerations and variable decelerations.66-68, 70 Contractions is described as 
frequency during 10 minutes and 5 or less is considered normal.67   
 
Figure 3. A normal admission CTG trace. 
                                   
 
However, there are different opinions about what is a normal baseline? How to describe 
decelerations? How important are accelerations? Most clinical guidelines divide CTG traces 
into three groups: Normal, suspicious/aberrant and pathological.34, 53, 66-68, 70 Dealing with 
normal and pathological traces is relatively standardized in most settings. A normal CTG 
trace can almost rule out hypoxia.64 The current debate concentrates on the suspicious traces. 
This group is also the most inconclusive in different CTG classifications.64, 65 
 
Inter- and intraobserver variability 
Despite many well established guidelines CTG interpretation is difficult. Several studies 
show large variation between and within different interpreters.71-77 Guidelines do not seem to 
decrease this issue.76 The problem is most explicit for baseline variability and decelerations.76 
However, updated guidelines and excessive education in interpretation seem to increase the 
unanimity.62, 78, 79    
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Adjunctive technologies  
Because of the high sensitivity and the low specificity in CTG interpretation there is a need 
for adjunctive technologies, especially in the low risk group where fetal distress is rare.51, 54, 
64, 65, 80, 81 The poor inter- and intraobserver reproducibility in the interpretation of a CTG 
trace make this even more important.71-77, 82 
The most common used adjunctive methods in Sweden are fetal scalp blood sampling (FBS) 
and ST-analysis of the fetal ECG (STAN).58 Computerized fetal intrapartum monitoring is 
another suggested method.72, 82-85 
 
STAN  
ST-analysis of the fetal ECG (STAN) is a complement to ordinary CTG. The theory is that a 
fetus exposed to hypoxia develops ECG changes similar to what is seen in myocardial 
infarcts.86, 87  
The fetal ECG is monitored through a scalp electrode and a reference electrode at the 
mother’s leg. A machine reports changes as ST-event in a trace combined with ordinary 
CTG. Whit the use of STAN the ordinary CTG interpretation is a baseline. When there is a 
normal CTG the ST-event is not relevant and should be ignored and if the CTG trace is 
ominous and defined “preterminal” according to the STAN-guidelines, the doctor should 
react without looking at the ST-events.86, 87  
The largest study comparing CTG with or without STAN is a RCT from the US, including 
11 108 women. In conclusion the results from this study are that there were no differences in 
neither intervention rates or neonatal outcome between labors monitored with CTG with or 
without STAN.88  
A Cochrane review was performed 2015 and includes seven RCT (27 403 women), where 
one is the RCT from the US mentioned above. The review concluded that less FBS were 
performed if STAN were used (RR 0.61; 95% CI 0.41-0.91), but only 9671 babies were 
included in this part of the study. There were also fewer operative vaginal deliveries if STAN 
was used (RR 0.92; 95% CI 0.86-0.99). The conclusion is that the weak possible benefits 
from the use of STAN need to be considered against the disadvantages with the method.89  
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Computerized CTG interpretation 
Computerized interpretation could be a way to eliminate the risk of human errors, and make 
the surveillance less user-dependent.  
Antenatal computerized CTG monitoring is an established method. It has been more 
complicated to create a computerized system for intrapartum monitoring, despite several 
attempts.  
 
Computerized antenatal monitoring 
A system for computerized antenatal monitoring was developed by Dawes and Redman 
during the 80ies and early 90ies. This group, the Oxford group has developed this system 
gradually and the system in use today is Sonicaid FetalCareTM. This system is a computerized 
monitoring system which combines ordinary CTG parameters with short-term-variation 
(STV) analysis in relation to specific criteria. The analysis is summarized with a conclusion: 
if Dawes Redman criteria are fulfilled or not.90-93 Fulfilled Dawes Redman Criteria is linked 
to vigorous fetuses and corresponds to a normal CTG trace.91, 93, 94  
This system is built of a complex algorithm with an even more complex flow-chart for the 
conclusion. Data analysis is performed after 10 minutes and then every two minutes. When 
the criteria are fulfilled or after 60 minutes the printer prints a summary (figure 4).90, 93 For 
the Dawes-Redman criteria to be fulfilled in summary these criteria’s need to be approved1: 
• At least one period with “increased variability” 
• STV > 3.0 msec. 
• Long-term-variation within 3 SD of the normalvalues or STV > 5 msec. 
• At least one fetal movement or 3 accelerations 
• Baseline between 116-160 beats per minute 
• No deep decelerations 
• No sinusoidal pattern 
• Signal loss < 30 % 
STV is an essential part of this criteria. The real STV (beat-to-beat variation in the fetal heart 
rate) is not possible to get from signal derived by an ultrasound transducer. STV can neither 
be estimated visually. The Oxford system therefore uses a computerized derived STV value. 
Firstly the system excludes part of the CTG trace with decelerations and signal loss. Then it 
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uses the epoch-to-epoch (3.75 second) variation as a measure of STV, calculating the 
difference between the average pulse-interval values for adjacent epochs. These values are 
then averaged over minutes and then over longer time periods. The reason for this is that 
periods with great signal loss mostly are periods with high activity and this calculation assure 
that these periods are equally weighted in the analysis.90-93  
A STV value of less than 3.0 msec correlates to stillbirth and severe birth acidemia.93, 95-99 
STV normally increases with gestational age and it is recommended, when possible, to use 
every single fetus as it owns control.91, 95 STV is an earlier sign of an affected fetus than 
decelerations, since it is computerized it is not either user dependent.91, 93 Computerized CTG 
monitoring is assumed to reduce perinatal mortality antepartum.100    
 
 
 
Figure 4. A report from the Sonicaid system. 
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Computerized intrapartum monitoring 
Intrapartum computerized monitoring is suggested to improve the inter- and intraobserver 
variability in CTG interpretation. There are great expectations. Many attempts have been 
performed, with different approaches, some including information about maternal and fetal 
characteristics.82, 101-103 Some groups have succeeded to develop system as good as 
experienced clinicians.82, 83, 104-106 
To develop a computerized intrapartum system is much more complicated than to develop an 
antenatal system.107 The CTG trace is more complex since the interpreter has to take 
contractions into consideration. The fetal heart rate is more dynamic, an effect of the 
autonomic nervous system due to the stressful situation. There are implications that 
intrapartum STV is higher than antenatal STV due to this stress.108 STV also increases 
towards the end of pregnancy.97 STV for intrapartum use is so far not fully evaluated.85, 108, 109 
When discussing the use of STV it is important to differ between STV as a stand-alone 
method and as a part of a system. Evaluation of STV as a stand-alone method has so far not 
shown any association to adverse outcome intrapartum, but the study size and that the 
included cases are mostly healthy might be an explanation.109 In a review from 2016 the 
conclusion is that STV appears to be a moderate predictor for fetal acidemia antenatally, but 
if it should be used alone or as part of a system  is not clear.110  
In this area it is important to differ between central fetal monitoring systems as MILOUTM 
and GuardianTM, and computerized CTG monitoring system as Omniview –SisPortoTM, 
INFANTTM and OxSysTM.111 In a very short time these three computerized CTG monitoring 
system have been presented and evaluated.  
A group in Portugal has developed Omniview-SisPortoTM 3.5 which is a monitoring system 
with visual and sounds alerts based on CTG and STAN. The system is constructed by 
commonly known CTG interpretation guidelines (FIGO guidelines).111, 112 This system is 
developed for both antepartum and intrapartum monitoring.113 The aim with this system and 
performed studies was to prove if this system could reduce the rate of umbilical cord artery 
metabolic acidosis compared to continuous CTG monitoring.114 Recently the results were 
published. It is a RCT performed in five clinics in United Kingdom. STAN and FBS were 
allowed in both study arms. 7730 women were randomized to the study. No differences were 
found either in primary or secondary outcomes. The authors highlights that there was a low 
rate of affected newborns in both study arms.105    
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The INFANTTM Collaborative group has performed a multicenter RCT (UK and Ireland) 
comparing continuous CTG with or without addition of a decision-support software 
(INFANTTM). INFANTTM is a supplement to the monitoring system GuardianTM. INFANTTM 
analyse the quality of fetal heart rate signals and displays baseline, variability, accelerations, 
type and timing of decelerations and contraction pattern. The system makes a conclusion 
from this material which ends up with a colour code there the colour code indicates the 
severity of the CTG changes. Their outcome was neonatal mortality or morbidity. They also 
performed a follow-up development assessment of a sample of children at 2 years age. 47 062 
women were recruited to the study. No significant differences were seen in any outcome, 
neither in mode of delivery. They conclude that computerized interpretation of CTG does not 
improve clinical outcome.106     
The Oxford group has developed a system called OxSysTM for intrapartum use.115 This is a 
CTG based system including STV.85 It uses the CTG interpretation guidelines from ACOG, 
but a bit modified due to computer reasons and combines this with STV in an algorithm. STV 
is calculated in the same way as in Sonicaid FetalCareTM.85 The results from this study are 
just published. They used a cohort of 22 790 laboring women to both develop and evaluate 
this system. Their conclusion is that the system is in concordance with clinical management. 
The system seems to be as good as clinicians.104  
Three experienced research groups have developed computerized systems for intrapartum 
monitoring. These systems seem to be as good as clinicians, if this is bad or good is a delicate 
question. 
 
Fetal scalp blood sampling (FBS)  
FBS was introduced parallel to CTG in the 1960ies. Saling introduced the method and early 
studies were performed by Beard. The method comprises of a small blood-sample from the 
fetal scalp, collected through an amnioscope at a vaginal exam of the woman in labor. The 
fetal blood is used for analysis to recognize if the fetus is suffering from acidosis as a sign of 
hypoxia. This method was introduced before CTG was widely available and fully 
evaluated.116-119  
Nearly 40 years after publication there is one single trial who still is remarkable in this area of 
research. The trial was performed in Denver, Colorado including 690 high risk pregnancies. It 
was a three armed trial comparing; auscultation, CTG and CTG with the option to take FBS. 
 20 
The trial showed no differences in neonatal outcome. The rates of caesarean section were 
significant higher in the CTG group compared to the auscultation group. The authors drew 
the conclusion that CTG did not improve neonatal outcome but increased the risk for 
caesarean. When looking at this trial more in detail, the auscultation group had only one 
caesarean due to fetal distress, meanwhile the CTG group had 16 caesareans due to fetal 
distress (7%), which was a significant difference. There was also a difference in caesarean 
rate than comparing CTG with or without FBS. In the group with FBS the caesareans due to 
fetal distress was 8 (3%). However, this difference was not significant. In their conclusion 
they wrote that if we should use CTG FBS may be required. In this study there was one-to-
one care which makes auscultation possible.120  
Initially, pH was analyzed in FBS sampling. The method requires 30-50 microliters blood 
and the analysis takes on average 47 seconds, but the total time for the method is often 
much longer. The fetus may have a low pH value because of either respiratory or metabolic 
acidosis. Early studies suggested a full blood gas analysis to differ between respiratory and 
metabolic acidosis.117 Lactate was first suggested in the 1980ies.121 The method was further 
developed in the middle of the 1990ies. This method only requires 5 microliters of blood 
and the analysis can be performed at the bedside in only 60 seconds.122 It is proven that the 
lactate concentration in the fetus is mainly of fetal origin.123-125  
Kruger et al performed a retrospective study of FBS and found that lactate is a more sensitive 
method than pH for predicting low Apgar score (<4 at 5 min) or moderate to severe hypoxic-
ischemic encephalopathy (HIE).126 They suggest cut-off values for lactate to 4.8 mmol/L 
(Lactate ProTM) and urged that it will result in the same amount of interventions as cut-off for 
pH 7.20. In the interpretation of lactate values the reference values between commercially 
available devices differ.127, 128   
Lactate concentration in FBS increase during second stage of labor.129, 130  Due to this 
different cut-off values have been suggested for first and second stage of labor.131  
In Sweden two RCT´s have been performed comparing pH and lactate in FBS. Westgren et al 
(1998) showed no differences in perinatal outcome or delivery mode between FBS with pH 
or lactate analyses, but they found more frequent unsuccessful sampling in the pH group.132 
Wiberg-Itzel et al performed a multicenter RCT comparing pH and lactate analyses at FBS 
(pH cut-off <7.21 and lactate >4.8 mmol/L) and found no differences in acidemia at birth. 
One conclusion from this study is that lactate has no false-negative tests.133 Wiberg-Itzel et al 
had protocol violations in 10.4 % in the pH group and 1.2% in the lactate group, due to failed 
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sampling or analysis. Lactate was analysed in high proportion of failed pH sampling, which 
was not allowed due to the protocol. This could have influenced the result in favour of pH, as 
without protocol violation the clinician could either deliver the fetus – with the effect of 
increasing the intervention rate – or let labor progress with risk of developing acidemia. It is 
likely to believe that pH sampling would have result in more operative deliveries if lactate is 
not available as an option.       
A Cochrane review was published in 2015 including the two Swedish RCT’s mentioned 
above (N=3348).134 The review concluded no difference in fetal outcome but a much better 
success rate in sampling with lactate.   
Holzmann et al performed a secondary analysis of the material from Wiberg-Itzel et al and 
looked at perinatal outcome in a subgroup of the 5% most acidemic fetuses defined as scalp 
pH below 7.17 or lactate over 6.6 mmol/l.133, 135 The authors found that neonatal morbidity 
occurred in 10% or less in this high-risk group. The conclusion was that FBS is an early 
marker which can be used to prevent severe birth acidemia and that lactate might be an earlier 
marker than pH because in the pH group the delivery were performed faster and still there 
were no differences in neonatal outcome.  
There are many supporters for the use of FBS even if the method so far has not been 
evaluated in any RCT large enough to proof a difference in CTG monitoring with and 
without FBS. There is also criticism towards the method.136 Criticism towards FBS concerns 
the fact that the fetal head is compressed during labor and that influence the blood flow to the 
fetal scalp. Opponents mean that the only reason for FBS still being in use is the lack of an 
alternative.137, 138 
Researchers seem to agree that if we should perform FBS lactate analysis has benefits 
compared to pH. It is easier to collect and most likely an earlier marker than pH.121, 127, 139, 
140 FBS is generally well tolerated by the women in labor.141 FBS reduces the proportion of 
false positive tests with CTG and is likely to reduce the rate of caesarean deliveries. 52, 116, 
120   
In the UK NICE guidelines recommends use of FBS.68 FBS is today used in all Swedish 
labor wards. 58    
Since Haverkamp performed the Denver trial 40 years ago there have been thoughts to repeat 
the same study but with a larger study population. 2015 a study protocol was published for 
the Flamigo trial. This was an Australian study which aimed to compare CTG and CTG with 
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FBS. The protocol caused great expectations.142 The planned recruitment according to the 
power analysis in the Australian New Zealand Clinical Trial register (march 2017) was 600 
women, but recruitment was stopped after 123 women. No results have been published so 
far.143   
A Dutch study is included in the Netherlands trial register; the SCALP trial. It is a multicentre 
RCT. Women were planned for monitoring with CTG with or without STAN and if the CTG 
became abnormal they would randomly be assigned to either FBS or not. Planned closing 
date was April 2015. So far no results have been published.144 
 
Maternal monitoring 
Labor dystocia is the most common reason for intrapartum caesarean section.32, 145 To 
monitor the contractions and the progress in labor we use the contraction pattern from the 
CTG and the partogram. The contractions are monitored by a transducer on the pregnant 
abdomen. It is possible to use either an external or an internal transducer. The internal 
transducer is a form of catheter which is introduced inside the uterus through a vaginal 
exam. Internal monitoring seems to give better information about the quality of 
contractions, but have not been proven to improve outcome.146 2017 the diagnosis dystocia 
is mainly a question of wait and see. 
    
Uterus physiology 
pH affects the effectiveness of the smooth muscles in the uterus. A low pH causes less 
frequent and weaker contractions.147, 148 It has been shown that human myometrial cells can 
produce lactate both under aerobic and anaerobic metabolism.149 A high concentration of 
lactate in myometrial tissue reduces both strength and frequency of contractions.150 Lactate 
effects the contractions by the change in pH.151 Capillary blood samples have been 
collected from the uterotomy in women who underwent caesarean section. These samples 
had a higher lactate concentration when the caesarean was due to dystocia compared to 
women who had normal progress of labor.150 
Lactate has previously been used in sports to evaluate performance.152, 153 Since the uterus 
is a working muscle it is a natural thought that it, like other muscles can be exhausted due 
to lactacidemia. The entire uterus receives blood supply from the internal iliac arteries 
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which supplies the body of uterus (corpus) as well as the cervix through the uterine 
arteries.154 
 
The Partogram  
In the 1950ies the partogram was developed and evaluated for monitoring progress in labor. 
The partogram is yet a central part of documentation in the labor ward. The alert and action 
line, which we still use as helpful tools in the diagnosis of dyctocia were introduced in the 
70ies. The cervicograph was developed in the US and the action and alert line were derived 
from data from a Rhodesian hospital.155, 156 The alert and action lines were developed to help 
midwives with limited access to obstetricians, to safely manage intrapartum care. In this early 
partograms an action line of four hours’ delay was used.157, 158         
The partogram is at present a clinical tool with unclear clinical value.159, 160 According to 
Cochrane there is no evidence for using the partogram, but the partogram may have an effect 
in areas with less access to healthcare resources.160 The partogram is nevertheless a useful 
tool in documentation.159  
 
Amniotic fluid lactate (AF-lac) 
One suggested method to predict dystocia is to measure lactate concentration in amniotic 
fluid (AF-lac). Regardless of stage of labor there are higher concentrations of lactate in 
amniotic fluid compared to FBS.161   
Studies have suggested that elevated AF-lac is associated with dystocia and caesarean or 
instrumental delivery. A discussed cut-off value is 10.1 mmol/l.162-164 AF-lac has been 
suggested as a complement to the partogram in predicting dystocia.165 Still the method has 
not been fully evaluated in any intervention study. 
The Stockholm County Health Technology Assessment (HTA) gave a statement of opinion 
in 2016. They concluded that it today is no indication to analyze AF-lac in laboring women 
to predict dystocia.166
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2 AIMS 
The general aim of this thesis was to investigate and improve established and new methods 
for intrapartum monitoring. 
 
The specific aims of each study were: 
• To methodologically study if short-term-variation (STV) is a possible 
complementary parameter to CTG in intrapartum fetal monitoring. (Study 1) 
 
• To investigate the association between different CTG patterns and lactacidemia in 
FBS. (Study 2) 
 
• To study the association between different potential intrapartum known risk factors 
and lactacidemia in FBS. (Study 3)  
 
• To study if cervical lactate could be a possible marker for labor dystocia and if 
maternal uterine and fetal scalp lactate correlates. (Study 4) 
 
 27 
 
3 MATERIALS AND METHODS 
Study 1 
Population and study design 
This is a prospective observational study. The study includes women at Karolinska 
University Hospital, Stockholm, Sweden between September 2011 and April 2015. Totally 
120 women were included in the study. The study is built of three subgroups (figure 5). 
 
Figure 5. Subgroups in study 1 
 
 
All women were monitored according to national and clinical guidelines for CTG 
surveillance.59 In subgroup A we collected STV values with internal monitoring. Table 3 
shows population characteristics. 
20 of the women in subgroup A is subgroup B. In these women we compared STV values 
derived from both external and internal monitoring, simultaneously. The twin function of the 
CTG machine made this possible. 
Subgroup C was simultaneously monitored with two different brands of CTG monitors, 
Sonicaid™ and EDAN™. Clinical indications for monitoring were suspected but not 
confirmed ruptured membranes, breech presentation prior to external cephalic version, 
admission test before induction of labor and maternal diabetes.  
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Table 3. Maternal, labor and neonatal data for study 1, subgroup A. 
Population characteristics numbers and medians (range) N=100  
Gestational age (days) 281 (261-296) 
Maternal age (years)      31 (17-43) 
Parity                                                             
                                                        Nulliparous                                                                         
Multiparous 
 
62                                                                                                        
38 
Mode of delivery 
Spontaneous                                     
Ventouse/forceps                              
Caesarean 
 
61                                                  
21                                                        
18 
Epidural 81 
Oxytocin infusion 55 
Apgar < 7 at 5 minutes 2 
Admission to NICU 8 
Birth weight (g) 3493 (2520-5030) 
 
STV 
SonicaidTM is an established CTG monitor for antenatal monitoring of STV with external 
Doppler monitoring. EDAN™ is a new CTG monitor which has equipment for both external 
Doppler and internal scalp electrode monitoring including a twin function. EDANTM is 
recommended for intrapartum monitoring, but the STV function has not previously been 
evaluated and is presently not recommended for clinical use. 
SonicaidTM and EDANTM use the same algorithm to estimate STV values. SonicaidTM 
presents one STV value at the end of the CTG trace either as soon as the Dawes-Redman 
criteria are fulfilled or after 60 minutes if the criteria are not fulfilled. EDANTM presents a 
first value after 10 minutes and then new values are added continuously up to 60 minutes. 
 29 
 
External fetal monitoring is performed by an ultrasound device on the woman’s abdomen, the 
internal monitoring through a scalp electrode on the fetus’s head detecting the time intervals 
between heart beats by identifying R waves on the fetal ECG.53 
 
Statistics 
For statistical analyses StatisticaTM version 10 (Statsoft Inc, Tulsa, OK) was used.  Data are 
presented as numbers, medians/means and standard deviations, when appropriate, percentage 
and range. Mann-Whitney U-test was used for comparison between continuous variables. 
Correlation between two parameters was calculated with Spearman Rank Correlation. 
Evaluation of agreement between different monitoring modes is displayed in Bland-Altman 
plots.  
 
Ethics 
The study was approved by the Regional Ethics committee in Stockholm (Dnr: 2014/2006-
31/4). Participants gave oral consent to participate in the study. 
All CTG traces were performed according to clinical indications. The information about STV 
values was no ground for clinical decisions. The only disadvantage for the participating 
woman was that she in some cases needed to have one or two extra abdominal probes during 
a short time period.   
 
Study 2 and 3 
Population and study design 
Study 2 is a prospective observational cohort study including women who underwent FBS 
due to a non-reassuring CTG trace. Study 3 is a secondary analysis of the same cohort. In 
study 2 the purpose was to correlate different CTG patterns to lactacidemia in FBS. Study 3 is 
an analysis of potential intrapartum known risk factors for lactacidemia in FBS. The cohort 
was collected at the labor ward Karolinska University Hospital, Stockholm, Sweden from 
February 2009 to February 2011 (table 4).  
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All laboring women who underwent FBS and had a simplex pregnancy, ≥ 34 weeks of 
gestation and with a fetus in cephalic presentation were included in the study (N=1070). 
During the study period FBS was performed in 10.5% (1070/10143) of all deliveries at 
Karolinska University Hospital.  
 
CTG 
All women were monitored with CTG according to Swedish guidelines.59 In conclusion this 
means that all women had an admission CTG, if the admission test was normal the woman 
was considered at low risk and intermittent CTG monitoring every two hours was 
recommended during first stage of labor. Women at high risk, having epidural analgesia or 
oxytocin augmentation had continuous CTG monitoring. During second stage of labor all 
women had continuous CTG monitoring. For CTG interpretation the department followed 
guidelines from SFOG. 
 
CTG classification 
All CTG traces 60 minutes prior to each FBS were retrospectively interpreted by a senior 
obstetrician (Lennart Nordström), blinded to the lactate concentration at sampling. For all 
traces baseline, variability, accelerations, type of decelerations and duration of CTG pattern 
were documented. FIGO definitions were used.167 All traces were divided into different 
groups according to the various CTG pattern (table 6-9). Simple variable decelerations and 
early decelerations were considered as normal. 
 
FBS 
The decision to perform FBS was made by the attending obstetrician. FBS were collected 
by a vaginal examination, 5 µL of fetal scalp blood was collected after wiping dry from 
amniotic fluid and applying silicone gel. Lactate Pro™ (KDK Corp. Kyoto, Japan) was used 
for all analysis. The cut-off value for acidemia was a lactate concentration above 4.8 
mmol/L, which was found in 94 (8.8%) of the cases.126 
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Table 4. Population characteristics for study 2 and 3. 
Population characteristics (N=1070)  Medians (range) and numbers (%) 
Maternal age (years)     31 (15-47) 
Gestational age (days)       283 (239-298) 
Parity                                                                   
                                            Nulliparous                                                      
Multiparous  
 
772 (72.1)                                                    
298 (27.9) 
Delivery mode                                                   
                                           Spontaneous                                                             
Ventouse                                                              
Caesarean 
 
418 (39.1)                                                    
352 (32.9)                                                 
300 (28.0) 
Previous caesarean                                                                                   
                                                          Yes                                                              
No 
 
109 (10.2)                                                    
961 (89.8) 
Maternal body mass indexa (N=1030)                                            
                                                       <18.5                         
18.5-24.9                                                               
25.0-29.9                                                                
30.0-34.9                                                              
>35.0     
 
32 (3.1)                                                       
620 (60.2)                                                 
253 (24.6)                                              
86 (8.3)                                                     
39 (3.8) 
Onset of labor                                                                 
                                           Spontaneous                                                      
Induced onset   
 
690 (64.5)                                                    
380 (35.5) 
Oxytocin at sampling                                                      
                                                            Yes                                                                                   
No     
 
652 (60.9)                                                   
418 (39.1) 
Epidural analgesia at sampling                                      
                                                          Yes                                                             
No 
 
862 (80.6)                                                   
208 (19.4) 
Birth weight (N=1068) (grams)         3510 (1638-5340) 
Apgar score <7 at 5 min                                             
                                                          Yes                                                             
No 
 
              15 (1.4)                                                                                                                      
d                         1055 (98.6) 
Hypoxic ischemic encephalopathyb (N=1061) 
Yes                                                                           
No 
 
 1 (0.09)                        
.                          1060 (99.9) 
a) Body mass index is equal to the weight (kilograms) divided with the square of the woman’s height 
(meters) 
b) Infant who had got the diagnosis hypoxic ischemic encephalopathy at discharge from the hospital 
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Risk factors 
Information on maternal, infant and intrapartum characteristics was collected from the 
medical records. Only factors known at sampling were included in the study. Nicotine use 
was defined as smoking or snuffing before or during pregnancy. Languages barriers were 
divided into none, minor or major. The woman was classified as having minor language 
barrier if a relative translated or 2nd language was used and as having major language 
barrier if professional interpreter was used. All intrapartum information was recorded as 
risk factors (intrapartum fever, epidural, oxytocin augmentation, active pushing) only if 
they have occurred prior to sampling. Birth weight was used as a proxy for intrauterine 
growth restriction, and fetal gender was also included in the database since it is possible to 
know at sampling. 
  
Statistics  
For statistical analyses StatisticaTM version 11 (Statsoft Inc. Tulsa, OK) was used for all 
analyses in study 2 and Statistica™ version 10 and 13 (Statsoft Inc. Tulsa, OK), were used 
for all analyses in study 3.   
In study 2 a power calculation was performed based on an interim analysis of 176 cases.  
Background data are presented as medians, range and percentages. Chi-square test and 
Fisher’s exact test were used for comparison of frequencies. Mann-Whitney U-test was used 
for comparison between groups.  
In study 3 logistic regression was used to calculate crude odds ratios (COR) and adjusted 
odds ratios (AOR) and their 95% confidence intervals (CI). Firstly a univariate analysis of 
potential risk factors was performed. If the p-value in the univariate analysis was <0.2 the 
risk factor was included in the stepwise forward multivariate logistic regression analysis.  
A p-value <0.05 was considered significant in both studies. 
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Ethics 
Study 2 and 3 were approved by the Regional ethics committee of Stockholm (2008/1618-31 
and 2011/478-32). All CTG traces and all FBS were performed upon clinical indication.  
    
Study 4 
Population and study design 
This is a clinical study performed at the labor ward at Karolinska University Hospital in 
Stockholm between May 2011 and February 2017. The population was recruited among 
women who underwent FBS due to non-reassuring fetal heart rate pattern. Characteristics 
of the study population are presented in table 5.    
 
Table 5. Characteristics of the study population. 
Population characteristics (N=77) (medians [range] and numbers [%]) 
Maternal age (year)                32 (19-43) 
Gestational age (days)              285 (249-296) 
Nulliparous                 59 (77) 
Previous caesarean                  7 (9) 
Maternal body mass indexa (kilogram/meter2)                25.5 (17-40) 
Induction of labor                 54 (70) 
Oxytocin infusion during labor                 68 (88) 
Intrapartum feverb                 35 (45) 
Epidural analgesia                72 (94) 
Delivery mode                                                        
                                                                          Spontaneous                                                
Ventouse/forceps                                                    
Caesarean 
 
22 (29)                                                                                                   
14 (18)                                       
41 (53) 
a) N=76  
b) Defined as 38 C degrees or more 
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Cervical lactate and amniotic fluid lactate sampling 
In addition to FBS for analysis of lactate concentration fluid samples from cervical tissue 
and when possible amniotic fluid were collected. To collect fluid samples from cervical 
tissue the same method as for FBS was used. The fluid collected from the cervix looked 
like a mixture of blood and extracellular fluid. If amniotic fluid was visible it was collected 
by putting a capillary in a suitable pouch. There were no technical problems with collecting 
Cx-lac, but AF-lac was not always visible. 
All analyses were performed bed-side using Lactate ProTM (KDK Corp. Kyoto, Japan). A 
method evaluated for FBS and AFL lactate concentration determination.126, 168  
The attending clinician was blinded to the Cx-lac and AF-lac value and the results were not 
used in clinical management. Afterwards maternal and labor information were collected 
and correlated to the results.    
 
Statistics 
For statistical analysis, we used Statistica for Windows version 10 (Statsoft Inc. Tulsa, OK, 
USA). Data are reported as medians, ranges and percentages. Chi-square test was 
performed for comparison of proportions and Mann-Whitney U-test or Kruskal-Wallis test 
were used for continuous variables. Correlation was calculated using Spearman Rank 
Correlation or linear regression. A p-value <0.05 was considered significant. 
 
Ethics 
The study was approved by the regional ethics committee of Stockholm (2011/1075-31/3).  
Since this study included invasive sampling participants got oral and written information 
about the study and gave consent to participate.  
The sampling did not cause the woman in labor any more inconvenience than the FBS did. 
All samples were destroyed after analysis.   
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4 RESULTS 
Study 1 
In subgroup A the median STV for all cases (N=100) was 7.1 msec (range 1.3-25.9). In 
comparison between early (cervix 3-6 cm) and late first stage of labor (7-10 cm) there were 
no differences (median 7.1 vs 6.8 msec; p=0.80) (figure 6). 
 
Figure 6. Box plot of STV and Cervical dilatation. 
 
 
 
All fetuses in subgroup B had at least 10 calculations of STV with simultaneous external 
and internal monitoring (in total 463 values). Median delta STV (internal-external) was 0.0 
msec (range -2.9 – 5.5). In the lower distribution of STV (<8 msec) the scalp electrode 
derived lower values compared to externally derived values. In the higher distribution of 
STV (>8msec) the result was the contrary. The correlation between STV from internal 
monitoring and delta STV (internal-external) was positive and significant (r=0.70; p<0.01) 
(figure 7).  
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Figure 7. Correlation between mean STV and delta STV. 
 
 
Subgroup C was simultaneously monitored externally with both brands of machines. The 
mean difference between STV Sonicaid and STV EDAN (delta-STV) was 0.6 msec (SD 
+1.17) (median 0.9 msec) within a range of -2.0 – 2.6. There was no significant correlation 
between STV Sonicaid and delta-STV (r=0.35; p=0.14) (figure 8). 
 
Figure 8. Bland-Altman plot: Mean STV and delta STV. 
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Study 2 
1070 women with 2134 FBS were included in the study. The results are presented both for 
first sampling (N=1070) and last sampling, since 52% of the women had more than one FBS. 
Women in active pushing prior to sampling are excluded in the analysis of women with late 
sampling.  
CTG interpretation prior to the first FBS shows that 23% of the cases had a normal CTG 
trace. In this study the definition of normal includes normal baseline and variability without 
serious decelerations. Simple variable and early decelerations were allowed. Isolated absence 
of accelerations was also considered as normal.  
Traces showed severe variable decelerations in 12% and late decelerations in 5% of the cases. 
The distribution of CTG patterns between the groups are presented in table 6.  
Cases with normal CTG pattern and cases with isolated reduced variability had a high amount 
of normal lactate concentrations at first FBS (97.5% and 97.4%) (table 6). There was no 
significant difference in comparison between amounts of lactacidemia (lactate > 4.8 mmol/L) 
between the groups.  
The highest frequency of elevated lactate concentrations was found in the groups with severe 
or late decelerations in combination with tachycardia (25% and 20% respectively) (table 6). 
These groups also had a higher median lactate concentration than the normal group (3.8 and 
3.1 mmol/l) (table 7). 
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Table 6. Proportions of fetal lactacidemia at 1st FBS in groups with different CTG patterns. 
CTG-pattern  Total numbers (%)  Numbers with lactate 
>4.8 mmol/L  
% (95% CI)  P-valuea  
Normal baseline and 
variability  
242 (22.6) 6 2.5 (0.1-4.5)  
Reduced variability 154 (14.4) 4 2.6 (0.1-5.1) 1.0  
Absent variability  32 (3.0) 4 12.5 (0.4-24.6) 0.020  
Increased variability  10 (0.9) 2 20.0 (0-50.2) 0.035  
Bradycardic episode  46 (4.3) 10 21.7 (9.4-34.1) <0.001  
Tachycardia  124 (11.6) 10 8.1 (3.2-12.9) 0.027  
Tachycardia + 
reduced variability  
149 (13.9) 9 6.0 (2.2-9.9) 0.102  
Severe variable 
decelerations  
127 (11.9) 18 14.2 (8.0-20.3) <0.001  
Late decelerations  58 (5.4) 8 13.8 (4.6-22.9) 0.001  
Severe variable 
decelerations + 
reduced variability  
28 (2.6) 4 14.3 (0.5-28.1) 0.013  
Late decelerations + 
reduced variability  
25 (2.3) 3 12.0 (0-25.7) 0.042  
Severe  variable 
decelerations + 
tachycardia  
32 (3.0) 8 25.0 (9.1-40.9) <0.001  
Late decelerations + 
tachycardia  
30 (2.8) 6 20.0 (4.8-35.2) 0.001  
Missing + 
undefinable pattern  
13 (1.2) 2 15.4 0.057  
Total  1070 94 8.8  
a) p-value calculated with two-tailed Fisher’s exact test in comparison with normal CTG 
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Table 7. Median of lactate concentration at first FBS in groups with different CTG patterns. 
CTG-pattern  Median (mmol/L)  5th – 95th percentile  P-valuea  
Normal baseline and variability (242)  2.2  1.3-4.3   
Reduced variability (154)  2.15  1.3-4.3  0.018  
Absent variability (32)  2.35  1.2-7.2  0.833  
Increased variability (10)  3.4  1.7-7.4  0.008  
Bradycardic episode (46)  3.15  1.4-6.3  <0.001  
Tachycardia (124)  2.4  1.6-5.3  0.013  
Tachycardia + reduced variability 
(149)  
2.4  1.4-5.0  0.223  
Severe variable decelerations (127)  3.2  1.7-6.7  <0.001  
Late decelerations (58)  3.2  1.8-6.3  <0.001  
Severe variable decelerations + 
reduced variability (28)  
3.1  1.8-6.9  <0.001  
Late decelerations + reduced 
variability (25)  
3.2  1.9-4.9  <0.001  
Severe variable decelerations + 
tachycardia (32)  
3.8  1.8-7.5  <0.001  
Late decelerations + tachycardia (30)  3.1  1.8-6.0  <0.001  
Missing + undefinable pattern (13)  3.2  1.3-6.8  0.478  
All groups (1070)  2.6  1.4-5.7   
a) p-value calculated with Mann-Whitney U-test comparison with normal baseline and variability 
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The results from the first FBS is in concordance with the results from the last FBS. In the 
group with a normal CTG trace 4.8% had an elevated concentration of lactate. CTG traces 
with late or severe variable decelerations were associated with high lactate concentration in 
22% of the cases (table 8).  
The CTG traces associated with highest amount of high lactate concentration were the one 
with severe or late decelerations with tachycardia (33% and 49%, respectively). In these 
groups the median lactate concentration was twice as high as in the group with a normal CTG 
trace (table 9). 
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Table 8. Proportions of fetal lactacidemia at last FBSa in groups with different CTG patterns. 
CTG-pattern  Total numbersa (%)  Numbers with lactate 
> 4.8 mmol/L  
% (95% CI)  P-valueb 
Normal baseline and variability  187 (21.1) 9 4.8 (1.7-7.9)  
Reduced variability  113 (12.7) 5 4.4 (0.6-8.3) 1.0  
Absent variability  32 (3.6) 7 21.9 (6.7-37.1) 0.003  
Increased variability  7 (0.8) 2 28.6 (0-73.7) 0.053  
Bradycardic episode  36 (4.1) 12 33.3 (17.2-49.5) <0.001  
Tachycardia  106 (11.9) 16 15.1 (8.2-22.0) 0.004  
Tachycardia + reduced variability  128 (14.4) 7 5.5 (1.5-9.5) 0.800  
Severe  variable decelerations  97 (10.9) 21 21.6 (13.3-30.0) <0.001  
Late decelerations  49 (5.5) 11 22.4 (10.3-34.6) <0.001  
Severe variable decelerations + 
reduced variability  
28 (3.2) 8 28.6 (10.7-46.4) <0.001  
Late decelerations + reduced 
variability  
34 (3.8) 10 29.4 (13.3-45.5) <0.001  
Severe variable decelerations + 
tachycardia  
33 (3.7) 16 48.5 (30.5-66.5) <0.001  
Late decelerations + tachycardia  30 (3.4) 10 33.3 (15.4-51.2) <0.001  
Missing + undefinable pattern  8 (0.9) 2 25.0 0.067  
Total  888 136 15.3  
a) Cases with active pushing prior to sampling excluded 
b) p-value calculated with two-tailed Fisher’s exact test in comparison with normal CTG 
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Table 9. Median of lactate concentration at last FBSa in groups with different CTG patterns. 
CTG-pattern (n)a  median (mmol/L)  5th – 95th percentile  P-valueb  
Normal baseline and variability (187)  2.3  1.4-4.8   
Reduced variability (113)  2.3  1.3-4.7  0.20  
Absent variability (32)  2.6  1.2-6.9  0.373  
Increased variability (7)  3.1  1.8-6.8  0.077  
Bradycardic episode (36)  3.3  1.3-8.7  <0.001  
Tachycardia(106)  3.0  1.7-6.3  <0.001  
Tachycardia + reduced variability (128)  2.5  1.4-5.2  0.204  
Severe  variable decelerations (97)  3.4  2.0-6.6  <0.001  
Late decelerations (49)  3.2  2.4-4.6  <0.001  
Severe variable decelerations + reduced 
variability (28)  
3.8  1.8-5.7  <0.001  
Late decelerations + reduced variability 
(34)  
4.5  2.7-6.8  <0.001  
Severe variable decelerations + 
tachycardia (33)  
4.4  1.9-7.5  <0.001  
Late decelerations + tachycardia (30)  4.2  2.1-6.3  <0.001  
Missing + undefinable pattern (8)  4.1  2.1-8.1  0.013  
Total (888)  2.8  2.1-4.0   
a) Cases with active pushing prior to sampling excluded 
b) p-value calculated with Mann-Whitney U-test comparison with normal baseline and variability 
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Study 3 
Firstly a univariate logistic regression was performed including 21 potential risk factors for 
lactate >4.8 mmol/L (table 10). In cases where repetitive scalp blood samples had been 
performed, only the first sample was included in this analysis.  
The analysis showed a significant result for language barriers (minor) (OR 2.54; CI 1.26-
5.11), stage of labor at sampling (active bearing down) (OR 2.46; CI 1.12-5.39) and 
maternal height (<155 cm) (OR 2.15; CI 1.08-4.26).  Epidural analgesia at sampling turned 
out as a significant protecting factor (OR 0.60; CI 0.37-0.97).     
An analysis of language barriers compared with maternal height showed that women with 
language barriers were significantly shorter than women without language barriers (13.4% 
of women with language barriers were <155 cm compared with 4.7% of women without 
language barriers; p<0.05). This information supported a theory that maternal height is an 
intermediate for language problems. Therefore maternal height was removed from further 
analysis. A multivariate logistic regression analysis was performed (table 11). Minor 
language barriers (OR 2.21; CI 1.05-4.67) and active pushing (OR 2.68; CI 1.20-6.00) 
turned out as significant risk factors. 
When excluding women in active pushing only epidural remained as a significant 
protecting factor (OR 0.54, CI 0.32-0.91).      
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Table 10. Univariate logistic regression 
Risk factors (N=1070) Numbers (%) OR (95% CI) p-value 
Language barriersa (N=1068)   
None                                                              
Minor                                                              
Major 
 
831 (77.8)
62 (5.8)
175 (16.4) 
 
Ref                       
2.54 (1.26-5.11)     
1.35 (0.78-2.34) 
 
     
0.009   
0.28 
Stage of labor at sampling (N=1014) 
Cervical dilatation 3-6 cm                          
Cervical dilatation 7-10 cm                          
Cervix fully dilated                                         
Active pushing  
 
340 (33.5)          
385 (38.0)          
237 (23.4)         
52 (5.1) 
 
Ref                         
0.87 (0.51-1.48)      
0.75 (0.40-1.41)    
2.46 (1.12-5.39) 
 
    
0.62   
0.37 
0.025 
Maternal height (N=1043) 
                                                 ≥155cm      
<155cm 
 
974 (93.4)      
69 (6.6) 
 
Ref                       
2.15 (1.08-4.26) 
 
     
0.028 
Epidural analgesia at sampling  
No                                                                      
Yes  
 
208 (19.4)
862 (80.6) 
 
Ref                        
0.60 (0.37-0.97) 
 
    
0.037 
Gestational age  
<41 weeks                                                          
≥41 weeks 
 
722 (67.5)
348 (32.5) 
 
Ref                        
1.53 (0.99-2.36) 
 
      
0.053 
Quality of amniotic fluid (N=1064) 
Normal                                                          
Otherb  
 
555 (52.2)
509 (47.8) 
 
Ref                       
1.50 (0.97-2.30) 
 
     
0.066 
Preeclampsia/hypertension  
No                                                                      
Yes 
 
988 (92.3)
82 (7.7) 
 
Ref                           
0.37 (0.12-1.21) 
                     
  
0.10 
In vitro fertilization  
No                                                                     
Yes  
 
1026 (95.9)
44 (4.1) 
 
Ref                        
0.23 (0.03-1.71) 
 
      
0.15 
Maternal age  
≤35 years                                                           
>35 years 
 
863 (80.7)
207 (19.3) 
 
Ref                       
1.31 (0.79-2.16) 
 
       
0.30 
Maternal body mass indexc (N=1030) 
<18,5                                                                         
18,5-24,9                                                            
25,0-29,9                                                           
30,0-34,9                                                           
>35,0 
 
32 (3.1)
620 (60.2)
253 (24.6)
86 (8.3)
39 (3.8) 
 
1.13 (0.33-3.84)    
Ref                       
1.04 (0.62-1.75)    
1.44 (0.70-2.95)    
0.59 (0.14-2.52) 
 
0.84                                  
Ref  
0.88  
0.32  
0.48 
Parity  
Nulliparous                                             
Multiparous without previous caesarean 
 
772 (72.1)    
189 (17.7)           
 
0.93 (0.54-1.61)     
Ref                       
 
0.80   
Ref
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Multiparous with previous caesarean  109 (10.2) 0.65 (0.26-1.61) 0.36 
Nicotine use prior to or during pregnancy 
(N=1055) 
No                                                                     
Yes 
 
                            
880 (83.4)
175 (16.6) 
 
                               
Ref                       
0.80 (0.44-1.48) 
 
                 
Ref  
0.48 
Time from rupture of membranes to sampling  
≤18 hours                                                          
>18 hours 
 
937 (87.6)
133 (12.4) 
 
Ref                        
0.83 (0.42-1.63) 
 
Ref
0.58 
Fever prior to sampling  
No                                                                     
Yes 
 
961 (89.8)
109 (10.2) 
 
Ref                       
1.19 (0.61-2.30) 
 
Ref  
0.61 
Oxytocin prior to sampling  
No                                                                     
Yes  
 
418 (39.1)
652 (60.9) 
 
Ref                       
0.90 (0.58-1.38) 
 
Ref  
0.61 
Time in active labor prior to sampling  
<12 hours                                                           
≥12 hours 
 
1010 (94.4)
60 (5.6) 
 
Ref                       
1.16 (0.49-2.78) 
 
       
0.73 
Fetal weightd (N=1068) 
Small for gestational age                      
Appropriate for gestational age                      
Large for gestational age 
 
  48 (4.5)   
987 (92.4)            
33 (3.1) 
 
1.17 (0.45-3.04)    
Ref                             
--- 
 
0.74   
Ref
0.99 
Fetal gender  
Female                                                             
Male 
 
518 (48.4)
552 (51.6) 
 
Ref                       
0.93 (0.61-1.42) 
 
Ref  
0.75 
Diabetese  
No                                                                      
Yes 
 
1042 (97.4)
28 (2.6) 
 
Ref                       
0.79 (0.19-3.40) 
 
Ref  
0.76 
Night time blood sampling  
7:00-19:00                                                     
19:00-7:00  
 
429 (40.1)
641 (59.9) 
 
Ref                       
1.03 (0.67-1.59) 
 
Ref
0.88 
Induced labor  
No                                                                     
Yes 
 
690 (64.5)
380 (35.5) 
 
Ref                       
1.03 (0.66-1.60) 
 
Ref  
0.89 
a) Major language barriers=assistance of interpreter 
Minor language barriers=not fluent Swedish-speaking, use of 2nd language or relative as interpreter 
b) Other=Blood or meconium in the amniotic fluid 
c) Maternal weight in kilograms divided by the square of maternal height in meters 
d) Small for gestational age is defined as fetal weight below two standard deviations  
   Large for gestational age is defined as fetal weight below two standard deviations 
 
e) Diabetes diagnosed in medical records at any time during the present pregnancy 
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Table 11. Multivariate logistic regression 
Risk factors (N=1070) Numbers (%) Adjusted OR 95% CI 
Language barriersa (N=1068) 
None 
Minor 
Major 
 
831 (77.8) 
              62 (5.8) 
175 (16.4) 
 
Ref 
2.21 
1.16 
 
 
1.05-4.67 
0.63-2.12 
Stage of labor at sampling (N=1014) 
Cervical dilatation 3-6 cm 
Cervical dilatation 7-10 cm 
Cervix fully dilated 
Active pushing 
 
340 (33.5) 
385 (38.0) 
237 (23.4) 
              52 (5.1) 
 
Ref 
1.03 
0.95 
2.68 
 
 
0.59-1.78 
0.49-1.83 
1.20-6.00 
Epidural analgesia at sampling 
No 
Yes 
 
208 (19.4) 
862 (80.6) 
 
Ref 
0.63 
 
 
0.38-1.07 
Gestational age 
<41 weeks 
≥41 weeks 
 
722 (67.5) 
348 (32.5) 
 
Ref 
1.39 
 
 
0.87-2.22 
Quality of amniotic fluid (N=1064) 
Normal 
Otherb 
 
555 (52.2) 
509 (47.8) 
 
Ref 
1.40 
 
 
0.88-2.22 
Preeclampsia/hypertension 
No 
Yes 
 
988 (92.3) 
              82 (7.7) 
 
Ref 
0.52 
 
 
0.16-1.73 
In vitro fertilization 
No 
Yes 
 
1026 (95.9) 
              44 (4.1) 
 
Ref 
0.30 
 
 
0.04-2.22 
a) Major language barriers = assistance of professional interpreter 
Minor language barriers = not fluent Swedish-speaking, use of 2nd language or relative as                                       
interpreter 
b) Other=Blood or meconium in the amniotic fluid 
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Study 4 
77 women in labor were included in the study. When including the first Cx-lac from every 
woman the median concentration of lactate was 3.7 mmol/L (range 1.1-14.8). 
Concentrations of Cx-lac differed between women with spontaneous and operative delivery 
(vaginal or caesarean) (median 2.9 vs 4.6 mmol/l; p<0.05) (figure 9). When dividing 
women into three groups according to mode of delivery (spontaneous, instrumental vaginal 
and caesarean) the results had the same tendency but were not significant (median 2.9 vs 
5.7 vs 4.2 mmol/l; p=0.07). 
 
Figure 9. Box-plot of cervical lactate by mode of delivery. 
 
 
Cx-lac concentration was compared between women who before sampling had or had not 
crossed a two hour delay action line in the partogram (4.6 vs 3.1 mmol/l; p=0.079). 
Correlations between cervical dilatation and Cx-lac (r=0.45; p<0.05), (figure 10), cervical 
dilatation and FBS-lactate (N=76; r=0.05; p=0.66) and FBS-lac and Cx-lac (N=76; r=0.35; 
p<0.05) were calculated. 
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Figure 10. Scatterplot: Cervical dilatation vs Cervical lactate 
 
 
 
Correlation between AF-lac and Cx-lac was also calculated (N=26; r=0.25; p=0.22). 
A univariate linear regression model between Cx-lac (independent) and FBS-lac 
(dependent) was performed, resulting in a β-value of 0.17 (R2=0.16; p<0.0007). Univariate 
linear regression with AF-lac as independent and Cx-lac as dependent variable (N=20) 
showed no significance (β=-0.04, R2=0.18; p=0.58).   
One concern was confounding due to a correlation between cervical dilatation and delivery 
mode. The women were therefore divided into two groups according to cervical dilatation 
(3 to 6 and 7 to 10 centimeters). The proportions of operative interventions were the same 
in the groups with lactate sampling in early and late first stage of labor (73.3% vs 68.8 %; 
p=0.66).    
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5 DISCUSSION 
Study 1 
Main findings 
Single values of STV from 100 women were collected with a median value of 7.1 msec 
(range 1.3-25.9). There was no difference in STV between early or late labor.  
In the comparison between internal and external monitoring the internal device calculated 
lower values than the external one in the lower range of STV (<8 msec), while the opposite 
was found in the higher range.  
STV values derived from Sonicaid Fetal Care™ and EDAN™ antenatal showed good 
agreement. 
 
Strengths and limitations 
It is a strength that the use of the CTG machines was performed by a limited amount of 
clinical staff aware of the method.  
The population is small and unselected. Therefor this material cannot be used to predict cut-
off values for STV in the identification of acidemic fetuses. 
A limitation when comparing the different brands of machines is differences in signal loss. 
This limitation is in principal eliminated by the fact that both machines have a limit for signal 
loss, where they no longer calculate STV.  
 
Interpretation  
Evaluation of a new method must start with methodological investigation. We need to know 
how to use the machine before we start to evaluate the method for clinical use. STV has been 
evaluated antenatally as a part of algorithms, but not appropriate as a stand-alone method or 
for intrapartum use.85, 91, 93, 94, 108-110   
The population in this study is too small and to selected to be useful in generating cut-off 
values for STV. Nevertheless, the material gives advices about how to continue in further 
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studies. All women in first stage of labor could be grouped irrespective cervical dilatation. 
Further intrapartum studies of STV should be performed with internal monitoring.     
The differences in STV between internal and external monitoring are most likely a true 
difference. External monitoring detects fetal heart rate from motions in the fetal heart and use 
the information to calculate STV. Internal monitoring is built on the fetal electrocardiogram a 
much more assured method. The clinical experience supports this. It is much more difficult to 
evaluate fetal heart rate variability in a CTG trace acquired with external monitoring than 
internal monitoring.  
SonicaidTM is previously well evaluated for antenatal use. Since EDANTM uses the same 
algorithm to calculate STV it was likely that the antenatal recordings would be in 
concordance. This finding confirms that the same cut-off values could be used antenatally. 
STV is a potential complement to CTG in intrapartum monitoring. The method is now 
evaluated in a computerized system.104 If STV works as a stand-alone method in intrapartum 
monitoring is not fully evaluated. Previous studies are small and the outcomes are rare. The 
method need a proper fully evaluation.   
 
Study 2 
Main findings 
A normal CTG trace or a CTG trace with isolated reduced variability is seldom associated 
with a high lactate concentration at FBS. Fetuses presenting CTG traces with severe variable 
decelerations and late decelerations had the same amount of high lactate concentration. The 
highest prevalence of elevated lactate concentration was among fetuses with CTG traces with 
late or severe variable decelerations and coexistence of tachycardia.  
 
Strengths and limitations 
The liberal use of FBS and the design with all laboring women included in the study are 
strengths in this study. Both in the study and in the labor department, strict CTG guidelines 
were used. There could be a question if it is a benefit that a single reviewer interpreted all 
CTG traces. A single experienced reviewer excludes all problems with interobserver 
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variability, so in this case it can be regarded as a strength. The CTG interpretation has after 
the study been validated in another study.79  
The limitation with largest impact is that we did not take the duration of CTG pattern into 
consideration. The analysis would have been too complex to draw clinical conclusions about. 
Another limitation is selection bias. Since we had a high amount of FBS sampling and even a 
large group with normal CTG traces there is unlikely that the threshold to take FBS has been 
too low. There is a chance that some severe CTG patterns have resulted in immediately 
delivery instead of FBS and that the results in the more severe CTG groups are even higher. It 
is unlikely that less severe CTG patterns resulted in the same so we consider our results in 
these groups reliable.           
 
Interpretation  
The reason for correlating CTG changes to FBS is the possibility to prevent fetal distress. 
There are few previous studies correlating intrapartum CTG changes to FBS.169-171 These 
studies were performed over 30 years ago and included between 85 and 279 women. A lot of 
changes have taken place both in CTG interpretation and FBS sampling since then. This is 
also the first study which correlates CTG changes to lactate in FBS, instead of pH.  
The finding that isolated reduced variability had the same amount of elevated lactate 
concentration as a normal CTG trace is clinically important. It means that we either should 
not perform FBS when a CTG trace shows isolated variability or just take a single sample to 
exclude acidemia. Isolated reduced variability should not be regarded as a sign of hypoxia.   
Previous studies have concluded that late decelerations are a severe sign. There is an 
association with chronic and acute hypoxia, often caused by a dysfunctional placenta.51, 172, 173  
Variable decelerations have another origin, usually from compression of the umbilical 
cord.174 Despite the differences in origin the results from this study shows similar proportions 
of lactacidemia in FBS for the two types of decelerations. This is a valuable finding since it 
makes differentiation between the types of decelerations less important and excludes a reason 
for interobserver variability.    
The great benefit with CTG is its high sensitivity. In this study, there is a frequency of 2.5% 
with elevated lactate concentration in the group with normal CTG traces. CTG has previously 
been considered to have a sensitivity of 80% detecting a cord artery pH below 7.17 by 
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CTG175 and 97% to detect a cord artery pH below 7.15.176 Compared to these results the 
sensitivity of 97.5% in this study is beyond expectation.   
 
Study 3 
Main findings 
This study suggests three significant risk factors for lactacidemia; language barriers, active 
pushing and maternal height less than 155 cm. Epidural analgesia seems to be a protecting 
factor in this study. 
 
Strengths and limitations 
The high proportion of deliveries monitored with FBS makes the results of this study more 
generalizable. Classification bias was minimized since only two persons, who worked close 
to each other, collected all data. 
The strongest limitation is that this study included 21 risk factors in a population of 1070 
women. These increase the risk of false positive results due to chance. Another limitation is 
that this is a secondary analysis of a previous study.177 
A possible problem in this study is the time component. To take away most of the effect of 
this problem all risk factors are just coded as risk factors if they were present at sampling. 
Active pushing could be a problem and therefore the analysis is also performed excluding 
women in active pushing.  
 
Interpretation 
That language barrier turned out as an independent risk factor among many other more 
general acceptable is notable. Previous studies have shown that immigration is a risk factor 
for different unsolicited outcomes in obstetrics.178-181  One suggested explanation is 
suboptimal care.182, 183 Communication problems are common among immigrants and it is 
therefore plausible that a part of the suboptimal care is language barriers. Since minor 
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language barriers was a risk factor but major was not it is likely to believe that this risk 
factor could be affected positively by routinely use of professional interpreters.   
The active part of second stage of labor is hard for the fetus, the contractions decreases 
placental perfusion and cause intermittent fetal hypoxemia. Previous studies support that 
this stage of labor is though for the fetus. Lower cord artery pH is found in vaginal 
deliveries compared to caesarean section during first stage of labor.184 Stable concentrations 
of lactate is found when performing FBS in first stage of normal labor, but during second 
stage of labor fetal scalp lactate increases with 1 mmol/l per 30 minutes of active bearing 
down.130 There are two ways to handle this information. One is to use higher cut-off values 
for interventions during second stage of labor.131 If so we need to proof and believe that 
lactate concentration has increased by physiological reasons during second stage of labor. It 
is unclear if it is physiological or represent that this part of the delivery is harder for the 
fetus. To secure the fetus we need to be careful when using FBS during second stage of 
labor. It is important to balance all information and to seriously consider assisted delivery if 
possible.    
Short stature has previously been correlated to adverse neonatal outcome.37, 185 In this study 
we could see a connection between short stature and language barriers, why we interpreted 
short stature as an intermediate factor. It is possible that short maternal stature is associated 
with low socioeconomic status, another known risk.5 Another explanation is that shortness 
is a risk factor for cephalo-pelvis disproportion.186, 187  
In previous studies epidural analgesia has been presented as a risk factor for adverse 
neonatal outcome.20, 37 This is opposite to the results from the present study. One 
explanation could be a healthy user effect ; healthy women with normal labors are more 
likely to get an epidural. An epidural could decrease the woman’s levels of stress-hormones 
and thereby have positive effects on the woman’s circulation and give better recovery 
potential for the fetus.188 Women with epidural analgesia are usually more monitored 
during labor and therefore they got the benefits of more present staff, a beneficial factor.189 
Surprisingly few of the previously known risk factor turned out as significant risk factors in 
this study. It is possible that knowledges about these risk factors might have affected 
clinical management.40, 190 
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Study 4 
Main findings 
It was easy to collect fluid samples from the cervix and the women seemed to tolerate the 
procedure well. The equipment for FBS was suitable to use. Since the fluid does not look 
like blood it is more appropriate to call it cervical fluid.  
There is an increase in Cx-lac with progress in labor. Lactate concentration in cervix 
correlates to mode of delivery and seems to be a risk factor for operative delivery. Fetal 
lactate is mainly of fetal origin and there is no increase in lactate concentration in fetal 
scalp blood with progress in labor.    
 
Strengths and Limitations 
The research group is experienced in research around FBS. The results from the analysis of 
Cx-lac and AF-lac were blinded for the attending obstetrician.  
The small study population is a limitation. This might have restricted the statistical power 
especially in the analysis including amniotic fluid. This study has a long study period 
compared to the population size, this is due to priority of another trial during a part of the 
study period.  
Only patients with indication for FBS were included in the study. This reduces the 
generalizability, but was necessary due to ethical reasons, since this method has not been 
evaluated before.  
 
Interpretation 
In sport medicine lactate is an established factor linked to performance.152, 153, 191 Since the 
uterus is a muscle it is likely to believe that lactate would affect the efficiency of uterine 
contractions. This is supported by previous studies of capillary blood samples from the 
hysterotomy at caesarean sections and a study that have linked increased concentration of 
lactate to decrease in the frequency and force of uterine contractions.147, 148, 150 The results 
from this study suggest that high concentration of Cx-lac correlates with the risk for 
operative delivery is in concordance with this. One more supportive finding in this direction 
would have been higher Cx-lac in women who had crossed a two-hour action line in the 
partogram compared to those who had not, the results in this study had a tendency towards 
this but were not significant (p=0.079). 
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In this study there was no significant correlation between lactate concentrations in cervical 
fluid and amniotic fluid (r=0.25; p=0.22). Previous studies have linked lactate 
concentrations in amniotic fluid to labor dystocia.162, 163 The results from the present study 
suggest that the lactate in amniotic fluid has other origin than the uterine muscle.   
There was no correlation between lactate concentration in FBS and cervical dilatation which 
is in concordance with previous studies.122, 123, 192 Since the linear regression model showed a 
β-value of 0.17 we consider that the transfer of lactate from uterus to fetus is limited, despite 
the finding of a moderate correlation between fetal scalp and cervical lactate (r=0.35), and the 
linear regression model is in line with previous studies.123, 124 
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6 CONCLUSIONS 
 
• Calculation of STV differs between internal and external monitoring. 
• There are no differences in STV between early and late first stage of labor. 
• Established antenatal cut-off values for SonicaidTM can be used for EDANTM. 
• STV might be a potential tool in intrapartum monitoring.  
• Isolated reduced variability is not associated with increased rate of fetal acidemia and 
therefore does not require repeated FBS. 
• Severe variable decelerations and late decelerations correlate equally with fetal 
acidemia. 
• Language barriers, active pushing and maternal short stature seem to be risk factors 
for intrapartum asphyxia. 
• A professional interpreter seems to decrease the risk for intrapartum asphyxia why all 
women with language barriers should be offered a professional interpreter. 
• During second stage of labor and especially during active pushing the fetus should be 
closely monitored and the value of FBS should be considered in relations to the effect 
of assisted vaginal deliveries. 
• Cervical lactate increases during the delivery process. 
• Cervical lactate do not contribute to the lactate levels in the fetus. 
• Cervical lactate is a possible clinical tool to predict the risk for operative delivery. 
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7 FUTURE PERSPECTIVES 
 
• The results from study 1 suggest several methodological findings to take into 
consideration in further studies of STV. Previously published articles stress the value 
of proper evaluation of STV both as a part in computerized intrapartum monitoring 
and as a stand alone method. Our research group has started a cooperation with KTH 
Royal Institute of Technology and has began the work to find intrapartum cut-off 
values for STV from a larger material derived from the intrapartum monitoring 
system MilouTM. If we succede in this a possibility would be a RCT to compare 
intrapartum CTG monitoring with or without STV.    
• During the study period for study 2 and 3 we performed FBS in 10.5% of all 
deliveries at Karolinska University Hospital in Solna. Since this cohort was collected 
SFOG has published new CTG guidelines, partly influenced by the study results from 
study 2. Thera have also been improvements in CTG education at the department. 
Today the FBS frequency is 2.8% of all deliveries and 3.1% if elective caesareans are 
excluded. There is a need to exclude that this decrease has affected outcomes. We 
therefore plan to perform a comparsion of neonatal outcomes and intervention rate 
between the study period for study 2 and 3 and 2016.       
• All intrapartum monitoring should be performed in a context. Previously published 
studies have suggested CTG differences between male and female fetal gender. Since 
we have access to a database with detailed interpretation of 2134 CTG traces we plan 
to perform a study comparing CTG patterns between male and female fetuses.     
• The results from study 3 suggests that language barriers is a risk factor for adverse 
nenonatal outcome, in the Swedish context. With an increasing immigrant population 
language barriers will be an important issue for health care professionals to deal with. 
Further studies are needed about how language barriers and access to interpreters 
affects medical outcomes as operative deliveries, frequency of perineal tears, bleeding 
complications and neonatal outcomes. 
• Our results from study 4 suggest that cervical lactate might be a predictor for 
operative deliveries. We would like to perform a bigger study with a more 
heterogeneous population with different progress in labor to evaluate how cervical 
lactate correlates with progress in labor and mode of delivery.    
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ 
SVENSKA 
 
Bakgrund 
Målet med förlossningsvård är alltid ett frisk nyfött barn till en välmående nybliven mamma, 
utan onödiga medicinska åtgärder eller ingrepp. Våra medicinska nödutgångar i form av 
sugklockeförlossningar och kejsarsnitt är säkra, men vi vet att för befolkningen som helhet är 
vinsterna med att hålla nere antalet ingrepp stora. För det enskilda barnet eller kvinnan kan 
dock ingreppet vara livsnödvändigt. För att veta hur vi skall hantera denna finstämda balans 
är våra övervakningsmetoder för förlossningar avgörande.  
För människan är födelsen livets största utmaning. Efter en oftast optimal tillvaro i livmodern 
påverkas fostret plötsligt av värkar. Värkarna påverkar blodtillförseln från kvinnan till fostret 
och detta kan under vissa omständigheter leda till syrebrist och mjölksyreansamling hos 
fostret. I mildare form kan fostret hantera detta och vårdpersonalen handla i tid, men i 
sällsynta fall leder detta fram till permanenta hjärnskador hos fostret. Allvarliga hjärnskador 
som t.ex. cerebral pares (CP) kan bero på syrebrist under förlossningen, även om det oftast 
beror på något annat.   
Inom läkarkåren och barnmorskekåren finns en stor erfarenhet. Vi baserar inte sällan våra 
beslut om särskild övervakning av kvinna och foster på just denna praktiska erfarenhet. 
Besluten blir då baserade på sådana karaktäristika och symtom som vi subjektivt uppfattar 
som riskfaktorer. Det finns därför ett behov av att dokumentera och systematisera våra 
erfarenheter så vi kan bevisa vad som verkligen är riskfaktorer för vad.  
För att övervaka fostret i magen använder vi i Sverige cardiotocografi (CTG) – hjärt-värk-
registrering. Via antingen en dosa på kvinnans mage eller en elektrod på fostrets huvud 
övervakas barnets hjärtfrekvens, förändringarna i hjärtfrekvens bedöms i relation till 
värkmönstret, som övervakas via ytterligare en dosa på kvinnans mage.  
När en CTG registrering är normal vet vi att fostret i magen mår bra. Vi kan också snabbt se 
om fostrat blir akut påverkat under förlossningen. Emellan dessa ytterligheter finns dock 
CTG registreringar som är svåra att bedöma. För att personalen på förlossningen skall veta 
hur fostret mår och hur de ska handlägga förlossningen vidare behövs då 
kompletteringsmetoder. 
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Den i Sverige idag oftast använda kompletteringsmetoden är skalpblodprov. Det innebär att 
en läkare gnom en gynekologisk undersökning tar ett litet blodprov från fostrets huvud 
(FBS). Det här blodprovet kan sedan analyseras inne på förlossningsrummet och de blivande 
föräldrarna får svar på mindre än en minut. I provet tittar man antingen efter hur surt blodet är 
(pH) eller efter mjölksyrakoncentrationen (laktat). Dessa värden visar på hur jobbigt fostret 
tycker att förlossningen är och därigenom på om man behöver vidta någon åtgärd. 
Den vanligaste orsaken till kejsarsnitt under pågående förlossning är inte hotande syrebrist 
hos barnet utan värksvaghet hos kvinnan. För att övervaka hur förlossningen går framåt 
använder vi i huvudsak upprepade gynekologiska undersökning där vi med våra fingrar 
uppskattar hur mycket livmodertappen har öppnat sig och hur långt barnets huvud har 
kommit ned. Resultaten av dessa undersökningar skriver vi in i ett partogram (en kurva över 
hur förlossningen framskrider), med stödlinjer för hur genomsnittsförlossningen framskrider. 
För att veta vilka kvinnor som drabbas av värksvaghet har vi idag inga andra verktyg, vilket 
innebär att tiden blir central. 
Tankar har funnits på om det finns någon metod för att tidigt i förlossningsförloppet ta reda 
på vilka kvinnor som löper risk för värksvaghet och kejsarsnitt p.g.a. detta. I tidigare studier 
har man visat att kvinnor som genomgår kejsarsnitt p.g.a. värksvaghet har högre halter av 
laktat i livmodermuskeln än vad kvinnor som genomgår kejsarsnitt av andra orsaker har. 
Detta har lett fram till frågan om en livmoder kan få ”mjölksyra” precis som en löpare eller 
skidåkare kan få. 
 
Studie 1 
Eftersom det är svårt att tolka CTG registreringar och det även förekommer stor variation i 
tolkningen mellan olika läkare och barnmorskor har tanken väckts om datoriserad CTG-
tolkning. Redan under 1980 talet utvecklades detta för CTG registrering under graviditeten, 
men under förlossningen blir fostrets hjärtrytm mer komplex och därför har det varit svårare 
att utveckla datoriserad tolkning för detta. I den datoriserade tolkning under graviditet läggs 
stor vikt vid korttidsvariabilitet (STV – short – term – variation), som är en teoretiskt 
uträknad slag till slag variation i fostrets hjärtrytm. Låga värden har visat sig korrelera med 
fosterdöd under graviditet.  
Studie 1 i denna avhandling är en metodologiskstudie som syftar till att utvärdera STV för 
förlossningsbruk. Vi har dels samlat in enskilda STV-värden från 100 kvinnor för att se hur 
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materialet fördelar sig. Vi har också jämfört STV-värden mellan tidig och sen förlossning och 
funnit att det inte finns någon skillnad. Vi har övervakat samma foster med både dosa på 
kvinnans mage och elektrod på huvudet och funnit att STV-värden skiljer sig åt mellan dessa 
metoder. Eftersom metoden inte tidigare används under förlossning har vi också jämfört 
maskinen för övervakning under graviditeten (sedan tidigare väl utvärderad) med en helt ny 
maskin som inte tidigare används för STV övervakning. Denna utvärdering visade att 
maskinerna är likvärdiga.  
Slutsatserna från denna studie är att det finns möjligheter att använda STV i 
förlossningsövervakning. Det är dock viktigt att skilja normalvärden mellan registrering med 
dosa på magen och registrering med elektrod vis fostrets huvud. De två CTG maskiner som 
finns på den svenska marknaden visar samstämmiga värden på STV och samma gränsvärden 
kan användas för båda maskinerna.  
 
Studie 2 
För att underlätta tolkning av CTG finns det riktlinjer för tolkning, i Sverige använder vi oss 
av Svensk förening för obstetrik och gynekologis (SFOG:s) riktlinjer. Enskilda CTG-mönster 
är i tidigare studier korrelerade till olika komplikationer hos det nyfödda barnet. I denna 
studie var syftet att gruppera CTG-kurvor efter olika mönster och jämföra laktatnivåer i 
fosterblodet (vid FBS) mellan de olika grupperna. Tanken var att genom att kunna veta vilka 
CTG-förändringar som speglar en påverkan på fostret under pågående förlossning kunna 
förhindra och inte förutse en hotande syrebrist.  
I denna studie fann vi att foster med normalt CTG och CTG med endast nedsatt variabilitet 
hade en låg risk för höga koncentrationer av laktat i blodet (2.5%). Nedsatt variabilitet har 
tidigare varit ett vanligt skäl till FBS och vetskapen om att denna förändring innebär en låg 
risk gör att vi kan minska antalet provtagningar.  
Högst risk för höga nivåer av laktat i blodet hade foster med en förhöjd grundnivå av 
hjärtfrekvensen kombinerat med olika typer av återkommande avancerade nedgångar i 
hjärtfrekvensen (20-25%). Dessa typer av nedgångar i hjärtfrekvens har helt olika 
fysiologiskt ursprung och vetskapen om att de är lika allvarliga förenklar arbetet med 
fosterövervakning.        
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Studie 3 
För att veta hur vi skall övervaka kvinnan och fostret under förlossningen behöver vi veta 
vilka riskfaktorer som vi behöver ta hänsyn till. Detta är tidigare studerat för olika typer av 
hjärnskador. Att veta vilka riskfaktorer som leder till hjärnskador är viktigt, men ännu 
viktigare är att veta vilka riskfaktorer som är kopplade till tidiga tecken på syrebrist och som 
därigenom kan hjälpa oss att förebygga detta.  
I denna studie har vi tittat på vilka riskfaktorer som finns för höga laktatvärden vid FBS. Vi 
vet att våra invandrarkvinnor löper större risker under förlossningen. Därför var en av de 
faktorer som vi studerade språkproblem (behovet av tolk). Denna studie visade att mindre 
språkproblem utgjorde en mer än fördubblad risk för höga laktat, jämfört med stora 
språkproblem som inte utgjorde någon risk. Kvinnor där anhöriga bistod med vissa 
översättningar eller kvinnor som kommunicerade via ett annat språk än svenska klassades att 
ha mindre språkproblem. Kvinnor som hade stöd av en professionell tolk på modersmålet 
klassades att ha stora språkproblem. Detta visar på behovet och vikten av att använda 
professionella tolkar inom förlossningsvården.  
Aktiv krystning utgjorde också en mer än fördubblad risk för höga laktat. Detta är känt sedan 
tidigare och stärker vikten av att övervaka mer aktivt och vara mer benägen till snabba 
åtgärder när en födande kvinna krystar.  
 
Studie 4 
I nuläget är det tiden som får utvisa om en födande kvinna har drabbats av värksvaghet. Att 
låta ett foster uppleva värkarbete utgör en bra förberedelse för att kunna födas, men vi vet att 
en långdragen förlossning ökar riskerna för komplikationer både hos fostret och kvinnan. 
I studie 4 har vi försökt hitta en möjligt sätt att förutse värksvaghet. Sedan tidigare vet vi att 
man har uppmätt höga nivåer av laktat i livmodern vid kejsarsnitt p.g.a. värksvaghet. Vid 
själva kejsarsnittet är redan beslutet om hur förlossningen skall avslutas gjort. För att kunna 
vara en hjälp i hur vi skall handlägga förlossningen behöver vi ha informationen tidigare.  
Under en förlossning är den enda del av livmodern som är tillgänglig för provtagning 
livmodertappen. I denna studie har vi därför via en gynekologisk undersökning tagit prover 
på vätskan i livmodertappen under aktiv förlossning och analyserat laktatkoncentrationen i 
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dessa. Informationen om dessa laktat värden har vi studerat i relation till hur förlossningen 
har framskridit, förlossningssätt och laktatnivåer hos fostret.  
I denna studie fann vi en skillnad i laktatkoncentrationer mellan kvinnor som födde spontant 
och kvinnor som blev förlösta med sugklocka eller kejsarsnitt. Vi såg också att 
laktatkoncentrationen steg ju mer livmodertappen öppnade sig. I jämförelsen mellan laktat i 
livmodertappen och laktat hos fostret kunde vi se att laktat i fostret i huvudsak produceras av 
fostret självt.  
Denna studie visar att det är möjligt att mäta laktat i livmodertappen och att det finns en 
möjlighet att laktatprovtagning skulle kunna vara ett sätt att förutse värksvaghet. 
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